Ranbaxy Announces Settlement Of Actos(R) (Pioglitazone Hydrochloride) Patent Litigation (PharmaceuticalOnline)
Ranbaxy Announces Settlement Of Actos(R) (Pioglitazone Hydrochloride) Patent Litigation (PharmaceuticalOnline)
Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc. (collectively, “Ranbaxy”), announced today that they have reached an agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Ranbaxy’s generic equivalent version of Actos (Pioglitazone Hydrochloride) 15 mg, 30 …